Quantcast

FDA approves new treatment for social anxiety disorder

The U.S. Food and Drug Administration has approved Effexor XR for the treatment of patients with social anxiety disorder, a condition which may affect up to 13 percent of Americans at some point in their lives. EFFEXOR XR, already approved for the treatment of depression and generalized anxiety disorder (GAD), is the first available serotonin-norepinephrine reuptake inhibitor (SNRI), and is believed to increase the levels of two key brain chemicals thought to be deficient in individuals suffering from depression and anxiety disorders.

Generalized anxiety disorder, peptic ulcers linked

A new finding of a link between an anxiety disorder and peptic ulcer disease lends support to the view that this gastrointestinal disease and anxiety disorder may share a common link. In recent years, attention has focused on a more biological element with the identification of bacteria as a cause of peptic ulcers. “The identification of Helicobacter pylori as an infectious cause of peptic ulcer disease has been considered by many to disprove the possibility that there is an important relationship between anxiety disorders and gastrointestinal disease,” says study author Renee D. Goodwin, Ph.D., from the Department of Epidemiology at the Mailman School of Public Health at Columbia University in New York City. “Over the last several years research on the causes and treatments for peptic ulcer disease has neglected the links with psychiatric/psychological factors,” she notes.